Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid
- 1 August 2008
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 38 (8), 635-637
- https://doi.org/10.1111/j.1445-5994.2007.01580.x
Abstract
The bisphosphonate zoledronic acid is commonly prescribed to prevent skeletal complications in patients with multiple myeloma or metastatic cancer. Although symptomatic hypocalcaemia is a potential risk of treatment, it has been thought to be uncommon.After seeing several episodes of symptomatic hypocalcaemia following zoledronic acid administration, we undertook a review to determine the incidence of this complication in our population and to attempt to identify risk factors.We reviewed the records of all patients receiving zoledronic acid in two teaching hospitals over a 2-year period. Findings collected included the indication for treatment, whether dosing was adjusted for creatinine clearance, coadministered medications, serum chemistries and clinical course.Of 120 patients who received a total of 546 zoledronic acid infusions, hypocalcaemia developed related to 55 infusions (10%) in 42 patients (35%). Symptomatic hypocalcaemia requiring i.v. supplementation occurred in 10 patients (8%), in spite of appropriate dose adjustment for creatinine clearance and despite prophylactic administration of oral calcium and vitamin D. More patients who became hypocalcaemic developed impairment of creatinine clearance during zoledronic acid treatment than in the group that remained normocalcaemic. Hypomagnesaemia was found in all patients who developed hypocalcaemia who had serum magnesium measured.Hypocalcaemia was common in our patient group following zoledronic acid treatment. Because of the prolonged elimination half-life of this agent (146 h), renal impairment occurring during a number of days after administration may increase risk. Hypomagnesaemia may further increase risk by blunting compensatory increase in parathyroid hormone secretion.Keywords
This publication has 9 references indexed in Scilit:
- Management of the adverse effects associated with intravenous bisphosphonatesAnnals of Oncology, 2006
- Bisphosphonates for malignancy-related bone disease: current status, future developmentsSupportive Care in Cancer, 2006
- Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myelomaInternal Medicine Journal, 2005
- Profound hypocalcaemia after zoledronic acid treatmentThe Medical Journal of Australia, 2005
- Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myelomaAnnals of Oncology, 2004
- Prolonged Hypocalcemia After Treatment With Zoledronic Acid in a Patient With Prostate Cancer and Vitamin D DeficiencyJournal of Clinical Oncology, 2004
- Severe hypocalcaemia after being given intravenous bisphosphonateBMJ, 2004
- Magnesium and the parathyroidCurrent Opinion in Nephrology and Hypertension, 2002
- Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical TrialsJournal of Clinical Oncology, 2001